Today: 30 June 2026
Alibaba stock drops into the weekend as China opens food-delivery probe; what BABA traders watch next
11 January 2026
1 min read

Alibaba stock drops into the weekend as China opens food-delivery probe; what BABA traders watch next

New York, January 11, 2026, 11:18 (EST) — Market closed.

Alibaba Group Holding’s U.S.-listed ADRs dropped 2.3%, closing at $150.96 on Friday. The decline came after China announced an investigation into aggressive competition among food-delivery platforms, drawing attention to the subsidy-heavy “instant retail” battle for one-hour delivery of products—from meals to over-the-counter medicine. Both Alibaba and rival Meituan said they welcome the probe and will cooperate. Reuters

This move matters now because delivery stands out as one of the clearest areas where Alibaba can boost user growth amid China’s packed consumer internet scene. It’s also a quick way to burn cash, making markets jittery about any spending shifts as U.S. trading kicks off again on Monday.

There’s a bigger issue here: policymakers aim to temper price wars without slashing demand. For Alibaba, this could translate into fewer discounts, rising compliance expenses, or pressure to alter its approach to merchants and couriers. None of that bodes well for neat forecasts.

China’s State Council announced the assessment will involve on-site inspections, interviews, and questionnaires, gathering input from merchants, workers, and consumers ahead of any proposed corrective steps. The commission in charge called on platforms to boost antitrust compliance and ensure fair competition.

The industry has been caught in a discount spiral for months. Kenneth Fong of UBS Investment Bank described the rivalry as a “high-stakes ‘game of chicken’,” while Moody’s Ratings analyst Ying Wang suggested that companies’ pledges to curb “involution” might “gradually rationalise” competition. Reuters

Alibaba highlighted faster delivery as a key growth driver. In November, the company surpassed quarterly revenue forecasts, boosted by investments in one-hour delivery that attracted more users to its shopping apps. Its cloud division also showed robust growth.

Rivals find themselves locked in the same battle. Meituan posted its first quarterly loss since late 2022 and signaled more losses ahead as a fierce price war with Alibaba and JD.com erodes margins, highlighting just how fast promotions can drain profits.

As the week kicks off, traders are on alert for any hint the regulator’s probe is shifting gears — whether that means softer subsidy offers, tougher merchant terms, or discussions around service-quality rules that could boost costs. If Alibaba changes course, it’ll probably surface first in tweaks to app traffic strategies and marketing budgets, rather than a big announcement.

The investigation cuts both ways. If platforms retreat too much, order growth could stall, pushing the battle toward other tactics — exclusive deals, delivery fees, or merchant commissions — which risk new scrutiny and consumer pushback. On the flip side, if Beijing falls short on effective measures, the price war could drag on, keeping margins razor-thin.

Alibaba’s upcoming quarterly earnings, slated for about Feb. 19 per Nasdaq’s earnings calendar, stand as the next major trigger for its stock.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Lululemon stock drops nearly 4% as tariff ruling stays unresolved — what to watch next
Previous Story

Lululemon stock drops nearly 4% as tariff ruling stays unresolved — what to watch next

Boeing stock climbs as FAA proposes new 737 inspections and investors eye delivery data
Next Story

Boeing stock climbs as FAA proposes new 737 inspections and investors eye delivery data

Go toTop